Published: Mar 15, 2021
VLP Therapeutics, Inc. (VLPT) announced that it has named Ms.
Miwa Toyoda, formerly a venture capitalist specialized in pharma and biotech at JAFCO Group Co., Ltd., as chief business officer, effective March 15, in a bid to accelerate its vaccine research and development projects and expand the portfolio.
Miwa s incredible skillset and experience will help expedite our vaccine projects and put the technologies to use.
From December 2014 to January 2021, Ms. Toyoda was a venture capitalist at JAFCO Group in Japan, where she led investments in five biotech/medtech companies at home and abroad, and served on the Boards or as an observer, providing hands-on support for their organization structuring, hiring, business development, fund raising, etc. She also provided business consultation as a specialist at the Medical Innovation Support Office (MEDISO) sponsored by the Japanese Ministry of Health, Labor and Welfare, and assistance with technology transfe
Fujitsu, Kyoto University Develop Explainable AI Verification System
Fujitsu Limited and a Kyoto University research group led by Professor Yasushi Okuno of the Kyoto University Graduate School of Medicine, has developed an AI verification system called MGeND Intelligence. When the genetic mutation information of a patient is input into this system, its ability to cause disease is estimated by pathogenicity estimation AI using machine learning technology and the explanatory text of the basis of this finding is generated and displayed together with the estimated result by the explainable AI. This explanation offers a useful reference to doctors who are considering a treatment plan or genomic medical researchers. The system draws from the Integrated Database of Clinical and Genomic Information program, managed by the Japan Agency for Medical Research and Development , and from April 2021, Kyoto University plans t